Mental health, 12.5% of the MCQ exam

Old age psychiatry

Dementia, delirium, late-life depression and behavioural and psychological symptoms of dementia (BPSD).

High-yield points

  • Distinguish delirium (acute, fluctuating attention) from dementia (gradual, memory first) and depression (pseudodementia).

  • Cognitive screening: MMSE or MoCA; RUDAS is designed for culturally and linguistically diverse patients; KICA is for Aboriginal patients in remote areas.

  • Exclude reversible causes: B12, folate, thyroid, calcium, glucose, syphilis/HIV where relevant, neuroimaging.

  • BPSD: look for pain, constipation, infection and environmental triggers first; use non-drug approaches before medication.

  • Antipsychotics in dementia increase stroke and death risk; if used, short-term and reviewed.

  • Donepezil, rivastigmine and galantamine help some people with Alzheimer's disease.

  • Plan early: enduring power of attorney, guardianship and advance care directive while the person has capacity.

India vs Australia

Where the answer the AMC marks correct differs from what’s usually taught in Indian MBBS.

  • Antipsychotics in dementia

    India (MBBS)

    Used freely for agitation.

    Australia (AMC): what the exam expects

    Non-drug approaches first. Risperidone is the only one PBS-subsidised for BPSD, limited to 12 weeks in Alzheimer's dementia.

  • Restraint

    India (MBBS)

    Not regulated in care homes.

    Australia (AMC): what the exam expects

    Chemical and physical restraint in aged care are 'restrictive practices' needing consent, documentation and review.

  • Delirium

    India (MBBS)

    Recognised clinically.

    Australia (AMC): what the exam expects

    Largely the same; screen with tools like the 4AT and find the cause.

  • Dementia support

    India (MBBS)

    Family carers.

    Australia (AMC): what the exam expects

    GP-led with memory clinic referral; Dementia Australia; plan capacity and substitute decision-making early.

The Australian context

Risperidone is the only antipsychotic PBS-subsidised for BPSD, limited to 12 weeks for severe symptoms in Alzheimer's dementia. Use of chemical and physical restraint in residential aged care is regulated as a 'restrictive practice' and needs consent and documentation.